We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge
Rejecting an appeal by Human Genome Sciences Inc (HGS), the Court of Appeal of England and Wales in Eli Lilly and Co v Human Genome Sciences Inc 2010 EWCA Civ 33 upheld the finding that HGS' patent (as amended) was invalid for lack of industrial applicability
The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily
